“I Don’t Need Those Pills”—Until the Second Heart Attack

Key Takeaways

• Ultra‑low LDL‑C target (<40 mg/dL) reduced major events 34% vs standard.
• 3,048 ASCVD patients; mean age 64, 21% women, 17 Korean sites.
• Median follow‑up 3.2 years; mean LDL‑C 35 mg/dL vs 62 mg/dL.
• Safety profile similar; no increase in liver or muscle adverse events.
• Supports guideline shift toward more aggressive lipid lowering in high‑risk groups.

Pulse Analysis

The Ez‑PAVE trial, presented at ACC 2026, is the first large‑scale study to directly compare two aggressive LDL‑C targets in patients with established ASCVD. Conducted across 17 South Korean centers between 2021 and 2022, the open‑label, randomized trial enrolled 3,048 adults (average age 64, 21% women) who had previously experienced myocardial infarction, stroke, stable angina, or peripheral artery disease. All participants received a statin backbone, with ezetimibe added to achieve either an ultra‑low LDL‑C goal of <40 mg/dL or a conventional target of <70 mg/dL.

After a median follow‑up of 3.2 years, the ultra‑low group achieved a mean LDL‑C of 35 mg/dL versus 62 mg/dL in the standard‑target arm. The primary composite endpoint—cardiovascular death, non‑fatal myocardial infarction, or ischemic stroke—occurred in 4.8% of the ultra‑low cohort compared with 7.3% of the standard cohort, translating to a relative risk reduction of 34% (p=0.02). Safety signals were modest; rates of hepatic enzyme elevation and myopathy did not differ significantly between groups.

These findings suggest that pushing LDL‑C below 40 mg/dL can further curb recurrent events in high‑risk patients, reinforcing the ‘lower is better’ paradigm that has guided recent guideline updates. For clinicians, the data support adding ezetimibe—or newer agents such as PCSK9 inhibitors—when statin therapy alone cannot reach ultra‑low thresholds. However, the modest absolute risk reduction and the need for intensive medication adherence highlight the importance of individualized treatment plans and cost‑effectiveness analyses before universal adoption.